Sushmita Panda is a New Delhi-based journalist with over six years of experience covering the healthcare and pharmaceutical sectors. She has reported on critical issues including drug patents and discovery, rare diseases, innovative therapies, women’s health, Neglected Tropical Diseases (NTDs), mental health, drug access, and regulatory affairs. Over the years, she has authored numerous in-depth stories and on-ground reports on diseases prevalent in India, including several exclusives and interviews with industry leaders. An alumna of the Asian College of Journalism and the University of Delhi, Sushmita has worked with national and international publications such as Financial Express, Sputnik, The Sunday Guardian, and India TV. When she’s not chasing stories, she enjoys reading and exploring new places.
Latest from Sushmita Panda
Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.
Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.